{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:32:42Z","timestamp":1786361562980,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Ewing sarcoma (ES) is a neoplasm of neuroectodermal origin arising from bone or soft tissue. The annual incidence of ES is 2.93 per 1,\u00a0000,\u00a0000. Acute myeloid leukemia (AML) is one of the most described second malignancies as a complication of primary cancer therapy. There is a lack of recent studies elaborating on the incidence rates of such complications. So, the aim was to quantify the risk of developing AML as a second primary malignancy (SPM) in ES patients and to provide an updated evidence to the literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We extracted the data from the Surveillance, Epidemiology and End Results (SEER) program statistical analysis software package (SEER*Stat, version 8.4.1.2). We used an MP-SIR session to identify patients diagnosed with AML as an SPM after ES as a first primary malignancy between 2000 and 2020. We assessed the SIR as Observed\/Expected(O\/E) and Excess Absolute Risk (EAR) per 10,\u00a0000 with a 95% confidence interval (CI) and statistical significance at 0.05.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 2631 patients with ES were recorded in the SEER database, with a median follow-up of 120\u00a0+\u00a0months. Patients with ES had an increased risk of developing AML with an O\/E of 145.98 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;\u00a00.05, EAR\u00a0=\u00a021.79). Gender played a role in AL development; both males (O\/E\u00a0=\u00a052.94,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;\u00a00.05, 95% CI: 31.87\u201382.670) and females (O\/E\u00a0=\u00a0105.62,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;\u00a00.05) had a high risk of AL SPM. About 35 patients developed acute non-lymphocytic leukemia with an O\/E 130.92 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;\u00a00.05, 95% CI: 91.19\u2212182.08, EAR 21.77). There was a significantly increased risk of developing SPMs in different sites among ES patients (O\/E\u00a0=\u00a05.85,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;\u00a00.05)\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Patients treated for a primary ES have a significant risk of developing AML, among other second primary malignancies. Thus, we recommend screening for AML from 2 to 11\u00a0months after the diagnosis of ES for early detection and better management outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000004455","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T10:00:10Z","timestamp":1764842410000},"page":"1243-1249","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The risk of developing acute myeloid leukemia in patients with Ewing sarcoma and trend analysis: a SEER-based study"],"prefix":"10.1097","volume":"88","author":[{"given":"Mohamed","family":"Zahed","sequence":"first","affiliation":[{"name":"John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa","family":"Ellaithy","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Suez Canal University, Ismailia, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alzahraa Faris","family":"Alesawy","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Benha University, Qalubiya, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahla","family":"Ali","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Alexandria University, Alexandria, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofian Mohamed","family":"Zreigh","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Ankara Yildirim Beyazit University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Eleisawy","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Benha University, Qalubiya, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3972-4950","authenticated-orcid":false,"given":"Bushra","family":"Al-Shaikh","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Sana\u2019a University, Sana\u2019a, Yemen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekram","family":"Hasanin","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Tripoli, Tripoli, Libya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saifaleslam Jamal","family":"Elsahli","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Misurata, Misurata, Libya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Faris","sequence":"additional","affiliation":[{"name":"Internal Medicine and Hematology department, Suez Canal University Hospital, Ismailia, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"R1-20260810","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3390\/cancers13061202","article-title":"Current status of management and outcome for patients with Ewing sarcoma","volume":"13","author":"Hesla","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R2-20260810","first-page":"405\u201312","article-title":"The diagnosis and treatment of osteosarcoma and Ewing\u2019s sarcoma in children and adolescents","volume":"120","author":"Zarghooni","year":"2023","journal-title":"Dtsch Arztebl Int"},{"key":"R3-20260810","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-018-0003-x","article-title":"Ewing sarcoma","volume":"4","author":"Gr\u00fcnewald","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"R4-20260810","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10081685","article-title":"Ewing sarcoma-diagnosis, treatment, clinical challenges and future perspectives","volume":"10","author":"Z\u00f6llner","year":"2021","journal-title":"J Clin Med"},{"key":"R5-20260810","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26562","article-title":"Morbidity and mortality after treatment of Ewing sarcoma: a single-institution experience","volume":"64","author":"Friedman","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"R6-20260810","first-page":"472\u201397","article-title":"Molecular and genomic landscapes in secondary & therapy related acute myeloid leukemia","volume":"11","author":"Goel","year":"2021","journal-title":"Am J Blood Res"},{"key":"R7-20260810","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.3390\/cancers14235920","article-title":"Secondary malignancies after ewing sarcoma-epidemiological and clinical analysis of an international trial registry","volume":"14","author":"Kaiser","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R8-20260810","doi-asserted-by":"crossref","first-page":"103607","DOI":"10.1016\/j.critrevonc.2022.103607","article-title":"Diagnosis and treatment of therapy-related acute myeloid leukemia","volume":"171","author":"Strickland","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"R9-20260810","doi-asserted-by":"crossref","first-page":"1272\u201383","DOI":"10.1093\/jnci\/djq278","article-title":"Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study","volume":"102","author":"Ginsberg","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"R10-20260810","doi-asserted-by":"crossref","first-page":"101269","DOI":"10.1016\/j.adro.2023.101269","article-title":"Effect of radiotherapy dose on outcome in nonmetastatic ewing sarcoma","volume":"8","author":"Kersting","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"R11-20260810","doi-asserted-by":"crossref","first-page":"493","DOI":"10.12688\/f1000research.18139.1","article-title":"Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children\u2019s Oncology Group (COG) new agents for ewing sarcoma task force","volume":"8","author":"Bailey","year":"2019","journal-title":"F1000Res"},{"key":"R12-20260810","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.3390\/cancers14081988","article-title":"Novel targeted therapeutic strategies for ewing sarcoma","volume":"14","author":"Fayzullina","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R13-20260810","doi-asserted-by":"crossref","first-page":"118\u201322","DOI":"10.1093\/jncimonographs\/lgae028","article-title":"The SEER Program\u2019s longstanding commitment to making cancer resources available","volume":"2024","author":"Murphy","year":"2024","journal-title":"J Natl Cancer Inst Monogr"},{"key":"R14-20260810","article-title":"Revised Strengthening the Reporting of Cohort, Cross-Sectional and Case-Control Studies in Surgery (STROCSS) guideline: an update for the age of Artificial Intelligence","volume":"2","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R15-20260810","doi-asserted-by":"crossref","first-page":"e27938","DOI":"10.1002\/pbc.27938","article-title":"Second malignancies in patients treated for Ewing sarcoma: a systematic review","volume":"66","author":"Caruso","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"R16-20260810","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112607","article-title":"Childhood cancer: occurrence, treatment and risk of second primary malignancies","volume":"13","author":"Zahnreich","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R17-20260810","doi-asserted-by":"crossref","first-page":"2551\u201360","DOI":"10.1002\/cncr.30627","article-title":"Longitudinal follow-up of adult survivors of Ewing sarcoma: a report from the childhood cancer survivor study","volume":"123","author":"Marina","year":"2017","journal-title":"Cancer"},{"key":"R18-20260810","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1097\/MPH.0000000000000924","article-title":"Development of secondary acute myeloid leukemia in a pediatric patient concurrently receiving primary therapy for ewing sarcoma","volume":"39","author":"McNew","year":"2017","journal-title":"J Pediatr Hematol Oncol"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000004455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:02:55Z","timestamp":1786359775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000004455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000004455","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"2025-08-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}